Genmab maintains 2026 revenue guidance at USD 4.33 billion to USD 4.53 billion
Bitget2026/11/05 16:18- Genmab maintained 2026 revenue guidance of USD 4.33 billion–USD 4.53 billion, implying 19% growth at the midpoint.
- Adjusted operating profit is forecast at USD 1.07 billion–USD 1.39 billion, with adjusted operating expenses of USD 2.81 billion–USD 2.95 billion.
- Spending targets accelerated late-stage development of petosemtamab and Rina-S, alongside launch preparations.
- EPKINLY sales and continued royalty portfolio momentum support the revenue outlook.
- Nine-month revenue rose 22% to USD 3.24 billion; adjusted operating profit increased 9% to USD 1.11 billion.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SoftBank develops contingency plans for slowdown in US data center business, considers shifting to other countries
A new twist has emerged in the US AI data center investment boom. SoftBank is preparing for cooling US demand and a deteriorating political environment, and does not rule out shifting data center construction priorities to other countries. As cross-border computing power delivery capability improves and investment returns come under question, the logic behind AI infrastructure expansion is loosening, and over $3.5 trillion in infrastructure investment now faces potential impairment risks.
Quantumrail Cancels 10 Billion Won Convertible Bond Offering
Crypto prices
More
